Filling the need for trusted information on national health issues…

Trending on kff Subsidies Marketplaces Enrollment

Vaccines

  • your selections
Clear Search

Filter Results

date

Tags

  • results
WHO Executive Board Meeting Addresses Agency’s Policy On Counterfeit, Substandard Medications

Intellectual Property Watch reports on how delegates at WHO’s executive board meeting used Wednesday to discuss WHO policy on counterfeit and substandard medications. According to the news service, WHO “members … raised strong concerns that a working group they mandated last May to address problems with WHO policy on counterfeit and substandard medicines has yet to be formed – with four months remaining before it must report back to members.”

Opinions: GAVI; Haitian Women; Clinton’s Foreign Policy

Sufficient Support Of GAVI Would Go Long Way To Preventing Premature Deaths Around The World  “Vaccines are among the greatest scientific contributions to human welfare. They are also some of the largest humanitarian contributions of developed nations to the rest of the world. So it is unfortunate that a decade of…

World Bank Announces Additional $5M Grant To Fight Cholera In Haiti

The World Bank on Tuesday “announced a $15 million grant to Haiti to fight a persistent cholera epidemic,” SAPA/Health24 reports. In a press release, the bank said it approved an additional $5 million to be added to a previously announced $10 million grant. “The funds, said the organisation in [the] statement, will go towards public campaigns to prevent infection and increase the capacity of Haiti’s health ministry to deal with the emergency,” the news service writes (1/19).

WHO Director-General Expresses Concern Over Public Mistrust Of Vaccines

During the WHO’s executive board meeting Monday, WHO Director-General Margaret Chan expressed concerns over what she called a “‘worrisome’ public mistrust of vaccines, following signs of a tail-off in flu vaccination,” Agence France-Presse reports (1/18).

RTS,S Offers 46 Percent Protection Against Malaria For At Least 15 Months After Vaccination, Study Finds

A Phase II trial published Friday in Lancet Infectious Diseases has shown that RTS,S, the “experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection” against malaria, Reuters reports. “Scientists conducting the mid-stage trial at the Kenya Medical Research Institute said results showing the shot offered 46 percent protection for 15 months meant it had ‘promise as a potential public health intervention against childhood malaria in malaria endemic countries’,” the news service notes (Kelland, 1/14).

Antibodies Produced By People Who Recovered From H1N1 Offer Clues For Universal Flu Vaccine

The antibodies produced by individuals who fought off H1N1 (swine flu) infection last year may bring researchers one step closer to their quest to develop a “universal” flu vaccine, U.S. researchers said Monday, HealthDay News/Bloomberg Businessweek reports. As the researchers from Emory University and the University of Chicago report in the Jan. 10 issue of the Journal of Experimental Medicine, “people who were infected with the H1N1 virus and recovered had a special immune response, producing antibodies that protect against a wide variety of flu strains,” the news service writes (1/10).

Also In Global Health News: NGOs, Business Schools; India’s Growing Presence In Africa; Water, Sanitation In Indonesia; Malaria Vaccine Trials

Financial Times Reports On Oxfam’s MBA Workshops Financial Times explores how the NGO Oxfam has started to “develop ethical trade workshops for MBA students in UK business schools, with a particular focus on overseas students” in the “hopes that by targeting the next generation of business leaders, it can influence…